1.0The Medical Xchangehttps://themedicalxchange.com/en/Adhesion Factor Inhibitors Fundamentally Shift Risk-Benefit of Biologics in IBD - The Medical Xchangerich600338<blockquote class="wp-embedded-content" data-secret="GzAXiYpwid"><a href="https://themedicalxchange.com/en/2013/06/06/digestive-disease-week-ddw-2013/">Adhesion Factor Inhibitors Fundamentally Shift Risk-Benefit of Biologics in IBD</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://themedicalxchange.com/en/2013/06/06/digestive-disease-week-ddw-2013/embed/#?secret=GzAXiYpwid" width="600" height="338" title="“Adhesion Factor Inhibitors Fundamentally Shift Risk-Benefit of Biologics in IBD” — The Medical Xchange" data-secret="GzAXiYpwid" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://themedicalxchange.com/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://themedicalxchange.com/wp-content/uploads/2013/06/MXCR-2338_Table_1_EN.PNG960720Orlando – Based on phase 3 trial evidence, adhesion factor inhibitors may fundamentally shift the risk-to-benefit ratio of biologics in the treatment of inflammatory bowel disease (IBD). The primary advantage, based on data with an agent likely to advance to regulatory approval, is an ability to confine biologic activity to the gut. Data from the trial program that was presented at this year’s Digestive Disease Week (DDW) demonstrated encouraging clinical remission rates at one year in both ulcerative colitis (UC) and Crohn's disease (CD). The remission rates suggest that localized inhibition of molecular processes fundamental to inflammation is effective. In addition, rates of infection and other markers of systemic immune suppression were similar to placebo.